Beth Andrews
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Antibiotic Resistance in Bacteria, Biochemical and Molecular Research, Tuberculosis Research and Epidemiology, Antifungal resistance and susceptibility
Most-Cited Works
- → Comparative Genomics ofHelicobacter pylori: Analysis of the Outer Membrane Protein Families(2000)327 cited
- → ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii(2017)267 cited
- → Transformation of Brassica napus L. using Agrobacterium tumefaciens: developmentally regulated expression of a reintroduced napin gene(1988)199 cited
- → Pyrrolamide DNA Gyrase Inhibitors: Fragment-Based Nuclear Magnetic Resonance Screening To Identify Antibacterial Agents(2011)134 cited
- → Inhibitors of the acetyltransferase domain of N-acetylglucosamine-1-phosphate-uridylyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Part 2: Optimization of physical properties leading to antibacterial aryl sulfonamides(2012)85 cited
- → Selective Inhibitors of Bacterial t-RNA-(N1G37) Methyltransferase (TrmD) That Demonstrate Novel Ordering of the Lid Domain(2013)54 cited
- → Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914(2015)51 cited
- → In Vivo Validation of Thymidylate Kinase (TMK) with a Rationally Designed, Selective Antibacterial Compound(2012)44 cited
- → In Vitro Validation of Acetyltransferase Activity of GlmU as an Antibacterial Target in Haemophilus influenzae(2011)41 cited
- → A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway(1996)37 cited